TRML
NASDAQ
US
Tourmaline Bio, Inc. - Common Stock
$47.98
+0.0 (+0.0%)
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.2B
ROE
-30.3%
D/E
0.00
Beta
1.86
52W
$12–$48
Wall Street Consensus
15 analysts · Feb 20262
Strong Buy
4
Buy
9
Hold
0
Sell
0
Strong Sell
40.0%
Buy Rating
Price Chart
Similar Stocks
BCAX
Bicara Therapeutics Inc
$922.0M
OLMA
Olema Pharmaceuticals Inc
$2.0B
ZBIO
Zenas Biopharma Inc
$2.3B
TSHA
Taysha Gene Therapies Inc
$1.5B
NVAX
Novavax Inc
P/E 3.2
$1.1B
CRVS
Corvus Pharmaceuticals Inc
$575.1M
SVRA
Savara Inc
$1.2B
AVBP
ArriVent BioPharma Inc
$830.6M
GERN
Geron Corp
$842.6M
KALV
Kalvista Pharmaceuticals Inc
$816.3M
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Jun 2025 | $-0.96 | $-0.90 | +$0.06 |
| Mar 2025 | $-0.93 | $-0.89 | +$0.04 |
| Dec 2024 | $-0.89 | $-0.86 | +$0.03 |
| Sep 2024 | $-0.83 | $-0.78 | +$0.05 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -30.3% | -30.3% | -30.4% | -30.4% | -30.3% | -30.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 24.90 | 24.90 | 24.68 | 24.68 | 24.90 | 24.90 |
Key Ratios
ROA (TTM)
-29.5%
P/B
1.7
EPS (TTM)
$-3.38
CF/Share
$-14.70
52W High
$48.27
52W Low
$11.56
$11.56
52-Week Range
$48.27
How does TRML compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
TRML valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.7
▼
30%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
TRML profitability vs Biotechnology peers
ROE
-30.3%
▲
55%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-29.5%
▲
37%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
TRML financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
24.9
▲
461%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.9
▲
92%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
TRML fundamentals radar
TRML
Peer median
Industry
TRML profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
TRML vs peers: key metrics
Latest News
No related news yet